Therapeutic blockade of the programmed cell death protein-1 (PD-1) immune checkpoint pathways has resulted in significant reactivation of T cell–mediated antitumor immunity and is a promising clinical anticancer treatment modality in several tumor types, but the durable response rate remains relatively low (15%–20%) in most patients with HCC for unknown reasons. Evidence reveals that the interferon signaling pathway plays a critical role in modulating the efficacy and sensitivity of anti–PD-1 therapy against multiple tumor types, but the mechanisms are unclear.

中文翻译：

---

肝干扰素调节因子 8 表达抑制肝细胞癌进展并增强抗程序性细胞死亡蛋白 1 疗法的反应

治疗性阻断程序性细胞死亡蛋白-1 (PD-1) 免疫检查点通路导致 T 细胞介导的抗肿瘤免疫显着重新激活，是多种肿瘤类型中一种有前途的临床抗癌治疗方式，但持久缓解率仍然相对较低大多数 HCC 患者的死亡率较低（15%–20%），原因不明。有证据表明，干扰素信号通路在调节抗 PD-1 疗法针对多种肿瘤类型的疗效和敏感性方面发挥着关键作用，但其机制尚不清楚。